Study of people with inflammatory bowel disease and fatty liver disease
Observes adults with inflammatory bowel disease who also have fatty liver disease.
Plain-language title generated from the registry record
Registry title: An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with inflammatory bowel disease (IBD) who also have fatty liver disease, and follows how the liver disease affects their IBD.
- Age
- Over 18 years (18 included).
- Sex
- All sexes can join.
- Disease stage
- IBD diagnosed according to the Chinese consensus on the diagnosis and treatment of IBD.
Main reasons for not taking part
- Incomplete clinical data
- Cannot cooperate with follow-up or refuses to sign informed consent
- Cannot cooperate with the required examinations
- Pregnant women
- Severe heart, lung, kidney or other organ disease or cancer, with expected survival under 6 months
Read by machine on 12 November 2026.
Where in China
- Shanghai East HospitalShanghai, ChinaContact: Lan ZhongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai East Hospital
- Trial code
- NCT06939569
- Record updated
- 23 April 2025
- Original description
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has increased dramatically in China, and it will become a common disease of digestive system in China. Mesenteric adipose tissue hyperplasia indicates disease activity in IBD patients, and abnormal lipid metabolism plays an important role in the pathogenesis of IBD.Read full original descriptionShow less
A Bidirectional, Multicenter Cohort Study of Inflammatory Bowel Disease (IBD) Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has increased dramatically in China, and it will become a common disease of digestive system in China. Mesenteric adipose tissue hyperplasia indicates disease activity in IBD patients, and abnormal lipid metabolism plays an important role in the pathogenesis of IBD.
In addition to intestinal symptoms, nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction associated fatty liver disease (MASLD), has become the most common extraintinal manifestation in IBD patients. What are the similarities and differences between IBD patients with and without MASLD? Does the occurrence and severity of MASLD affect the clinical efficacy of IBD and increase the adverse outcome of IBD? There are no relevant studies to date. We have previously completed the construction of a cohort of 290 IBD patients using the IBD patient database and biobank of Dongfang Hospital, based on which we completed a cohort study on the effect of small intestinal bacterial overgrowth on IBD disease activity. Based on this cohort, multi-center cooperation was carried out to establish an IBD research cohort by collecting basic clinical information and biological samples such as peripheral blood and intestinal mucosa. The clinical characteristics of IBD patients with MASLD were analyzed. logistic regression, COX regression, Kaplan-Meier survival curve and other methods were used. To investigate the effect of MASLD on the clinical efficacy and prognosis of inflammatory bowel disease (IBD). This project will provide efficient, full and reliable research-grade data with Chinese characteristics for IBD clinical research, and improve the level of regional diagnosis and treatment.
Inclusion: Subjects aged over 18 years (including borderline values), of either sex; Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD; Subjects able to cooperate with follow-up, participate in this study and sign the informed consent.
Exclusion: Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women; 5.Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months; Subjects with incomplete clinical data; Subjects can not to cooperate with follow-up, and refuse to sign the informed consent.